29 Jul 2021

Curia Fine Chemicals Catalog

PDF 128 kB

Fine Chemicals Catalog

Content provided by our supplier


  • US
  • 2015
    On CPhI since
  • 4
  • 1000 - 4999

Other Content from AMRI

  • News Curia lays out plans to expand complex API manufacturing capacity

    The $35 million investment will more than double the site’s batch-size scaling and product output.
  • News Curia to buy fellow CDMO Integrity Bio

    Acquisition will add West Coast coverage to the CDMO's East Coast and European capabilities and enhance its biologics formulation development and fill-finish network
  • Brochure Curia Company Overview

    From early discovery and development through manufacturing and commercialization, Curia’s suite of custom solutions allows us to tailor every engagement to your precise needs, whether that’s an independent project or an opportunity that spans the drug development lifecycle.
  • News Building supply chain resiliency to ensure access to medicines 

    With CPhI North America fast approaching, we ask Karen Flynn (President, Biologics & Chief Commercial Officer, at Catalent), Hamilton Lenox (Senior Vice President of Business Development, Sales & Marketing, at LGM Pharma), and Mike Kleppinger, Chief Commercial Officer, at AMRI) to weigh in on strategies the industry can use to build supply chain resiliency which ensure uninterrupted access to medicines
  • Brochure Curia Development Overview

    Drawing from diverse branches of chemistry, biology, physics, engineering and pharmaceutical sciences, Curia provides scientific expertise and state-of-the-art technology to solve your most complex challenges and deliver integrated pharmaceutical drug development programs from preclinical to commercial. We provide development services at locations within the United States and Europe. Our process development services are strategically located to deliver timely execution through convenient local points of contact.
  • Brochure Curia Drug Product Overview

    Curia offers comprehensive development and manufacturing services to meet needs through the entire life cycle of your sterile drug product. Leverage our in-depth expertise and capabilities at any scale, from early clinical through large-scale commercial.
  • Brochure Curia API Overview

    Curia is one of the largest independent developers and suppliers of APIs to the life sciences industry. Our complete suite of capabilities supports the chemical development and cGMP manufacture of complex APIs,including but not limited to potent and cytotoxic compounds and controlled substances. With world-class facilities in North America, Europe and Asia,we provide the scale and technology to serve your needs from development to manufacturing, for small to commercial-sized batches. Curia has a track record of quality and compliance with the FDA, AIFA, PMDA and other regulatory agencies and more than 550 API DMPs filed worldwide.
  • Brochure Curia Discovery Overview

    Curia’s comprehensive drug discovery services include biology,synthetic and medicinal chemistry, DMPK and bioanalytical services that span the continuum from hit-to-lead identification through candidate selection. Our solutions offer reduced compound testing cycle times, efficient internal sample transfer and rapid, data-driven decision making. Capitalize on the value of our integrated drug discovery centers of excellence that combine scientific expertise and leading-edge technology to accelerate innovation.